Jefferis Remains Positive on Shares of Ardea Biosciences (RDEA) Following 28-Week Extension Data For Lesinurad-Allopurinol Combination
Tweet Send to a Friend
Jefferies is reiterating its Buy rating and $32 price target on shares of Ardea Biosciences (NASDAQ: RDEA) following positive 28-week ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
